Fenwick Represents EpiBiologics in $107M Series B Funding

Fenwick represented EpiBiologics, a leader in tissue-selective extracellular protein degradation, in its $107 million Series B funding. The round was co-led by GV and Johnson & Johnson with participation from Novartis Venture Fund (NVF), Aulis Capital, Avego BioScience Capital, Samsara BioCapital, Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital.

EpiBiologics will use the funds to advance its pipeline of novel bispecific antibodies. More information can be obtained here.

The Fenwick transaction team was led by corporate partners Matt Rossiter and Effie Toshav and included associates Adam Conway, Kaylee Johnson, Warren Pugash, and Jonathan Archer.